Revenues - Summary of Transaction Price and Allocation of Transaction Price to the Performance Obligations (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Jan. 31, 2024	Jan. 29, 2024	Jan. 28, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Premium from Third Stock Purchase Agreement Amendment			$ 87
Option continuation payment received in the third quarter of 2024			100
Deferred revenue as of January 2024		$ 335	335
Total transaction price	$ 319		522		$ 398
Allocation To Performance Obligations	35
Inflammation target 1 - R&D services
Disaggregation of Revenue [Line Items]
Allocation To Performance Obligations	18
Inflammation target 2 - R&D services
Disaggregation of Revenue [Line Items]
Allocation To Performance Obligations	17
Gilead
Disaggregation of Revenue [Line Items]
Total transaction price			522
Gilead | Etrumadenant - License and R&D services
Disaggregation of Revenue [Line Items]
Total transaction price	166		210	$ 129	133
Gilead | Quemliclustat - License and R&D services
Disaggregation of Revenue [Line Items]
Total transaction price	23		168	$ 130	132
Gilead | Domvanalimab - R&D services
Disaggregation of Revenue [Line Items]
Total transaction price	21		33		$ 25
Gilead | Access rights
Disaggregation of Revenue [Line Items]
Total transaction price			57
Gilead | Option continuation periods
Disaggregation of Revenue [Line Items]
Total transaction price			20
Gilead | Rights to certain studies
Disaggregation of Revenue [Line Items]
Total transaction price	$ 34		$ 34